Biotech Values

[stocksrising]

ZURICH, Nov 26 (Reuters) - Switzerland's Roche will acquire its U.S. collaboration partner Poseida Therapeutics in a cash deal worth up to $1.5 billion, banking on complex immune cell therapies against several types of blood cancer to boost its development pipeline.
Roche will pay $9 per share in cash and stockholders will also receive a non-tradeable contingent value right for up to $4 per share based on achievements, the companies said in a statement on Tuesday, taking the deal value to up to around $1.5 billion.
It is expected to close in the first quarter of 2025.